Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia
Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia
复制标题
第 90 天的微小残留病监测可预测 T 细胞急性淋巴细胞白血病儿科患者的长期生存
DOI：
10.1080/10428194.2020.1805739
复制
发表时间：
2020-08-10
影响因子：
2.6
通讯作者：
Zhu, Xiaofan
中科院分区：
文献类型：
--
作者：
Liu, Xiaoming;Zou, Yao;Zhu, Xiaofan
目的探讨小儿T细胞急性淋巴细胞白血病（T-ALL）微小残留病（MRD）监测的最佳时机。新诊断的T-ALL患儿在我院按照CCLG-ALL 2008方案进行治疗。在第15、33和90天监测MRD，并根据第33和90天的MRD将患者分层为低风险、中等风险或高风险。所有患者的5年无事件生存率（EFS）和总生存率（OS）分别为60.1 ± 5.6%和63.1 ± 5.6%。中位随访时间为54（0.3-120）个月。单变量分析显示，5年EFS率与第33天和第90天的MRD相关（p <0.01）。多因素分析表明，只有第90天的MRD和中枢神经系统（CNS）的参与是独立的预后因素。第90天的MRD可能为儿童T-ALL患者提供更好的预后价值。临床试验注册：ClinicalTrials.gov标识符：NCT 00707083
Abstract To evaluate the optimal time to monitor minimal residual disease (MRD) for pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL). Children newly diagnosed with T-ALL were treated per the CCLG-ALL2008 protocol in our hospital. MRD was monitored at days 15, 33 and 90, and the patients were stratified as low-, intermediate- or high-risk according to MRD at days 33 and 90. The 5-year event-free survival (EFS) and overall survival (OS) rates for all patients were 60.1 ± 5.6% and 63.1 ± 5.6%, respectively. The median follow-up time was 54 (0.3–120) months. Univariate analysis showed that the 5-year EFS rate correlated with MRD at days 33 and 90 (p < .01). Multivariate analysis demonstrated that only MRD at day 90 and involvement of the central nervous system (CNS) were independent prognostic factors. MRD at day 90 likely provides better prognostic value for pediatric T-ALL patients. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00707083